Newron Pharmaceuticals S.p.A.

Equities

NWRN

IT0004147952

Pharmaceuticals

Delayed Swiss Exchange 11:31:16 2024-03-28 am EDT 5-day change 1st Jan Change
7.74 CHF -1.28% Intraday chart for Newron Pharmaceuticals S.p.A. -0.26% +57.58%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Newron Pharmaceuticals S.p.A., 2023 Earnings Call, Mar 19, 2024
Newron Pharmaceuticals' FY23 Loss Narrows; Revenue Up MT
Newron Pharmaceuticals S.p.A. Announces Agreement with the European Investment Bank to Extend the Near-Term Tranche Repayment Dates of Its 2018 Financing Agreement CI
Newron Pharmaceuticals Secures Extension on Three Loan Repayments MT
Newron Pharmaceuticals Investor Subscribes for Nearly EUR6 Million Shares MT
Swiss Equities Edge Higher as Markets Continue to Weigh Rate Cut Outlook MT
Transcript : Newron Pharmaceuticals S.p.A. - Special Call
Newron Reports Exceptional One-Year Results of Study 014/15 with Evenamide in Treatment-Resistant Schizophrenia CI
Newron Pharmaceuticals' Schizophrenia Drug Lowers Disease Severity in Clinical Studies MT
Swiss Equities Rally as Economic Barometer Hits Eight-month High at Year-end MT
Newron Pharmaceuticals Completes Enrolment of Schizophrenia Patients for Evenamide Clinical Study MT
Newron Pharmaceuticals S.p.A. Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A with Evenamide CI
Newron Pharmaceuticals S.P.A. Presents New Data from Study 014/015 Evaluating Its Investigational Drug Evenamide for the Management of Treatment Resistant Schizophrenia CI
Newron Pharmaceuticals S.p.A. Appoints Margarita Chavez as Board Advisor CI
Newron Pharmaceuticals S.p.A.(SWX:NWRN) added to S&P Global BMI Index CI
Newron Pharmaceuticals Net Loss Narrows in H1; Revenue Grows MT
Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Newron Pharmaceuticals S.P.A. Announces Marco Caremi, Executive Vice President Business Development Will Leave the Company as Per End of June 2023 CI
Newron Pharmaceuticals Promotes Finance VP to CFO MT
Newron Pharmaceuticals S.p.A. Presents Six-Month Interim Data from the First 100 Patients Randomized in Study 014/015 At the 31St European Congress of Psychiatry CI
Newron Pharmaceuticals S.p.A. Reports Compelling Topline Results from All Patients in Study 014, its Phase II Clinical Trial Evaluating Evenamide as Add-On Therapy for Treatment-Resistant Schizophrenia CI
Newron Pharmaceuticals' Schizophrenia Drug Shows Significant Improvement in Efficacy MT
Transcript : Newron Pharmaceuticals S.p.A., 2022 Earnings Call, Mar 14, 2023
Newron Pharmaceuticals' Net Loss Widens in FY22 MT
Chart Newron Pharmaceuticals S.p.A.
More charts
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
8.003 EUR
Average target price
13.28 EUR
Spread / Average Target
+65.96%
Consensus

Annual profits - Rate of surprise